red-stars.com data AG
Operative holding company based in Vienna investing in mission-critical digitalization and life science technologies.
Funder analysis
Web-researched analysis· 25 Jul 2026· v7What they fund
The firm funds early-stage B2B SaaS businesses in telecom, connectivity management, EDI, and cloud migration [1]. It also invests in life sciences, particularly longevity and drug development platforms based on human brain and heart organoids derived from iPS cells [1]. Investments require a foundation of globally leading technologies and proprietary IP [1].
Investment thesis
red-stars.com data AG operates as an operative holding company, investing in and managing firms that deliver mission-critical products and offerings to enable digitalization [1]. The firm targets early-stage B2B SaaS businesses, specifically focusing on telecom and connectivity management, electronic data interchange (EDI), cloud migration, and life sciences [1]. Investments are grounded in globally leading technologies, proprietary IP, and patents [1]. The holding structure allows for active management and strategic cooperation with VCs, multinational industry partners, family offices, and high-net-worth individuals (HNWIs) [1].
Credibility: Thomas Streimelweger's Wikipedia entry details the firm's operational model, investment focus on B2B SaaS and life sciences, and its reliance on proprietary IP and patents [1].
Value add
red-stars.com data AG provides active management through its operative holding structure, leveraging Thomas Streimelweger's extensive network and experience [1]. The firm cooperates and co-invests with VCs, multinational industry partners, family offices, and HNWIs, offering strategic partnerships and capital [1].
Fit verdict: Ideal for B2B SaaS and life science companies with proprietary IP seeking strategic partners and active management.
Founder diligence script:
- How does the operative holding structure impact day-to-day operational autonomy?
- What specific strategic partnerships or co-investors are typically brought in?
- How does the firm support the commercialization of proprietary IP and patents?
- What is the expected timeline for achieving mission-critical product status?
Portfolio focus
The portfolio clusters around mission-critical B2B SaaS and life science technologies, often leveraging proprietary IP and patents [1]. Specific portfolio companies are not named in the available documentation, but the firm's history includes S&T AG, a leading IT-integrator in Eastern Europe [1].
Notable investments & exits
Thomas Streimelweger founded S&T AG, a leading IT-integrator in Eastern Europe, which he took public in 1998 on the EASDAQ/NASDAQ Europe [1]. This represents a significant exit and success story associated with the firm's founder.
Strategic implications
red-stars.com data AG's operative holding structure provides a unique advantage in actively managing and scaling mission-critical technologies, particularly in B2B SaaS and life sciences. The firm's reliance on proprietary IP and patents suggests a high barrier to entry for competitors, but also a dependency on continuous innovation. The firm's network of VCs, multinational industry partners, family offices, and HNWIs offers significant strategic value, but also requires careful management of diverse stakeholder interests.
Where they could go further
The firm could benefit from more transparent communication about its portfolio companies and investment strategy to attract more strategic partners and co-investors. Expanding its focus to include emerging technologies in digitalization, such as AI and blockchain, could diversify its portfolio and mitigate risks. Establishing a more formalized co-investment process with its network of VCs and industry partners could enhance deal flow and strategic alignment.